Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash & Equivalents (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Cash & Equivalents readings, the most recent being $4.9 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 88.03% to $4.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Mar 2026, up 88.03% year-over-year, with the annual reading at $15.6 million for FY2025, 417.26% up from the prior year.
  • Cash & Equivalents hit $4.9 million in Q1 2026 for DiaMedica Therapeutics, down from $15.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $15.6 million in Q4 2025 and bottomed at $2.1 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $4.8 million, with a median of $3.3 million recorded in 2025.
  • The largest annual shift saw Cash & Equivalents tumbled 82.92% in 2022 before it surged 417.26% in 2025.
  • DiaMedica Therapeutics' Cash & Equivalents stood at $4.7 million in 2022, then dropped by 3.91% to $4.5 million in 2023, then plummeted by 33.41% to $3.0 million in 2024, then surged by 417.26% to $15.6 million in 2025, then plummeted by 68.89% to $4.9 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Cash & Equivalents are $4.9 million (Q1 2026), $15.6 million (Q4 2025), and $3.3 million (Q3 2025).